Chief Medical and Innovation Officer · NovoCure Ltd (NVCR)

Uri Weinberg

A named executive officer of NovoCure in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$4,159,945

FY2024: $5,055,906

4th of 6 named executive officers at NovoCure by FY2025 total.

6 named officers on file for NovoCure, FY2025

See an example →

What this number hides

The filing gives the total. NovoCure’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how NovoCure’s whole pay program stands against its peers

  • NovoCure’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NVCR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 20, 2026 (DEF 14A).

Free

Get Uri Weinberg’s full pay file as a PDF — free

More than this page: up to 10 years of Uri’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Uri Weinberg and every company like it: Velarion Intel, free for 3 days, no card →

Uri Weinberg compensation by year

NovoCure Summary Compensation Table · all 2 fiscal years held
In US dollars, as NovoCure reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$471,483$541,102
Bonus$0$0
Stock awards$2,666,647$1,999,991
Option awards$1,336,659$1,001,020
Non-equity incentive$226,473$270,551
Pension and deferred compensation$0$0
All other$354,644$347,281
Total$5,055,906$4,159,945

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NovoCure Ltd DEF 14A filed April 20, 2026, accession 0001645113-26-000033, and prior-year filings. Open the filing on EDGAR.

How this page was built: the NovoCure Ltd filed document, accession 0001645113-26-000033. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2026.

$5.1M
$4.2M
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
PSU81,799$1,057,661—
RSU54,975$710,827—
PSU54,975$710,827—
RSU54,532$705,099—
PSU12,992$167,987—
RSU4,330$55,987—
Option81,499—$18.19
Option93,808—$16.30
Option10,803—$76.97
Option7,605—$80.59

Per the Outstanding Equity Awards at Fiscal Year-End table in NovoCure Ltd's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments NovoCure discloses, by trigger · FY2025
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$405,810$0$0$405,810
Resignation for good reason, no change in control$405,810$0$0$405,810
Change in control and involuntary termination$811,620$1,471,912$0$2,283,532
Change in control and resignation for good reason$811,620$1,471,912$0$2,283,532

Per the Potential Payments Upon Termination or Change in Control table in NovoCure Ltd's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.

NovoCure’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Ashley CordovaFormer Chief Executive Officer$13,198,354
Frank LeonardChief Executive Officer$6,975,329
Christoph BrackmannChief Financial Officer$4,163,398
Uri Weinberg · this pageChief Medical and Innovation Officer$4,159,945
Nicolas LeupinFormer Chief Medical Officer$3,999,041
Michael PuriChief Human Resources Officer$3,933,893

Uri Weinberg's compensation dossier, NovoCure

You have read Uri Weinberg's totals and holdings. The dossier adds each equity grant NovoCure disclosed for Uri Weinberg and NovoCure's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full NovoCure compensation record

free company brief

This page is one person within NovoCure's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the NovoCure proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NovoCure's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NovoCure's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order NVCR

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Uri Weinberg's compensation dossier